throbber
L-Cysteine Hydrochloride 50 mg/mL Injection
`
`Page 1 of 5
`
`
`
`COVID-19 Resources
`
`
`
`PUBLISHED SEPTEMBER 20, 2011
`L-Cysteine Hydrochloride 50 mg/mL Injection
`
`Loyd V. Allen, Jr., PhD
`Professor Emeritus
`College of Pharmacy, University of Oklahoma
`Oklahoma City, Oklahoma
`
`US Pharm. 2011;36(9):41-42.
`
`Method of Preparation: Note: This formulation should be prepared
`according to strict aseptic compounding technique in a laminar airflow
`hood in a cleanroom or via isolation barrier technology by a
`compounding pharmacist who is validated in aseptic compounding.
`This is a high-risk preparation.
`
`https://www.uspharmacist.com/article/l-cysteine-hydrochloride-50-mgml-injection
`
`5/7/2020
`
`Eton Ex. 1020
`1 of 5
`
`

`

`L-Cysteine Hydrochloride 50 mg/mL Injection
`
`Page 2 of 5
`
`Calculate the quantity of each ingredient for the amount to be prepared.
`Accurately weigh or measure each ingredient. Mix the cysteine in about
`40 mL of Sterile Water for Injection. Add sufficient hydrochloric acid 2N
`solution to a pH of 1 to 2.5 to form a clear solution. Add sufficient
`Sterile Water for Injection to final volume; mix well. Filter into sterile
`containers. Package and label.
`
`Use: This injection solution is intended for use only after dilution as an
`additive to crystalline amino acid injections to meet the nutritional
`amino acid requirements of infants receiving total parenteral nutrition
`(TPN).
`
`Packaging: Package in tight, light-resistant containers.
`
`Labeling: Keep out of the reach of children. Discard after ____ [time
`period]. Protect from light. Discard if precipitation occurs. Store at
`controlled room temperature. Do not freeze.
`
`Stability: A beyond-use date of up to 24 hours at room temperature or 3
`days in the refrigerator may be used if not sterility tested. If sterility
`tested, a beyond-use date of up to 6 months may be used.
`1
`
`Quality Control: Quality-control assessment can include weight/volume,
`physical observation, pH, specific gravity, osmolality, assay, color,
`clarity, particulate matter, sterility, and pyrogenicity.
`2,3
`
`Discussion: Premature or sick infants may receive TPN before starting
`other feedings or when they cannot absorb nutrients through the
`gastrointestinal tract for a significant period of time. TPN confers a
`level of nutrition that is superior to standard IV feedings, which provide
`simply sugars and salts. L-Cysteine hydrochloride 50 mg/mL injection is
`used for TPN in infants.
`4
`
`L-Cysteine hydrochloride 50 mg/mL injection has been in short supply.
`The formulation presented here can be compounded for use until the
`manufactured product is available.
`
`https://www.uspharmacist.com/article/l-cysteine-hydrochloride-50-mgml-injection
`
`5/7/2020
`
`Eton Ex. 1020
`2 of 5
`
`

`

`L-Cysteine Hydrochloride 50 mg/mL Injection
`
`Page 3 of 5
`
`Cysteine Hydrochloride Injection, USP, is a sterile solution of cysteine
`hydrochloride in water for injection. It is a clear, colorless solution with
`an odor of sulfide. It contains not less than 85.0% and not more than
`115.0% of the labeled amount of cysteine hydrochloride. The product
`contains not more than 0.7 USP endotoxin units per mg of cysteine
`hydrochloride and has a pH between 1.0 and 2.5.
`5
`
`L-Cysteine hydrochloride (L-cysteine, L-cysteine ethylester
`hydrochloride, C H NO S.HCl.H 0, MW 175.63) is a nonessential amino
`3
`7
`2
`2
`acid in human development. It is freely soluble in water, alcohol, acetic
`acid, and ammonia water, but is insoluble in ether, acetone, ethyl
`acetate, benzene, carbon disulfide, and carbon tetrachloride. In neutral
`or slightly alkaline aqueous solutions, it is oxidized to cystine by air. It is
`more stable in acidic solutions.
`
`Hydrochloric acid (HCl, MW 36.46) occurs as a clear, colorless, fuming
`aqueous solution of hydrogen chloride that has a pungent odor.
`Concentrated hydrochloric acid is 36.5% to 38.0% w/w concentration. It
`has a specific gravity of 1.18 g/cm , is miscible with water, and is
`3
`soluble in ethanol. The pH of a 10% v/v aqueous solution is 0.1.
`Hydrochloric acid should be stored in well-closed glass or other inert
`containers.
`6
`
`Sterile Water for Injection is water for injection that has been sterilized
`and suitably packaged; it contains no added substances. Water for
`injection is water purified by distillation or reverse osmosis and
`contains no added substances. Water for injection is not prepared by an
`ion-exchange process. The term water is used to describe potable water
`from a public water supply that is suitable for drinking and is the
`beginning point of the official waters. It is a clear, colorless, odorless,
`and tasteless liquid. Purified water is obtained by distillation, ion
`exchange, reverse osmosis, or other suitable process. Water has a
`specific gravity of 0.9971 at room temperature, a melting point of 0°C,
`and a boiling point of 100°C. It is miscible with most polar solvents and
`is chemically stable in all physical states (ice, liquid, and steam).
`7
`
`https://www.uspharmacist.com/article/l-cysteine-hydrochloride-50-mgml-injection
`
`5/7/2020
`
`Eton Ex. 1020
`3 of 5
`
`

`

`L-Cysteine Hydrochloride 50 mg/mL Injection
`
`Page 4 of 5
`
`REFERENCES
`1. USP Pharmacists’ Pharmacopeia. 2nd ed. Rockville, MD: US Pharmacopeial Convention, Inc;
`2008:775-779,797-831.
`2. Allen LV Jr. Standard operating procedure for particulate testing for sterile products. IJPC.
`1998;2:78.
`3. Allen LV Jr. Standard operating procedure: quality assessment for injectable solutions. IJPC.
`1999;3:406-407.
`4. Total parenteral nutrition—infants. Medline Plus. www.nlm.nih.gov/medlineplus/
`ency/article/007239.htm. Accessed August 12, 2011.
`5. U.S. Pharmacopeia 34/National Formulary 29. Rockville, MD: US Pharmacopeial Convention,
`Inc; 2011:2464.
`6. Quinn ME, Sheskey PJ. Hydrochloric acid. In: Rowe RC, Sheskey PJ, Quinn ME, eds. Handbook
`of Pharmaceutical Excipients. 6th ed. London, England: Pharmaceutical Press; 2009:308-309.
`7. Dubash D, Shah U. Water. In: Rowe RC, Sheskey PJ, Quinn ME, eds. Handbook of
`Pharmaceutical Excipients. 6th ed. London, England: Pharmaceutical Press; 2009:766-770.
`
`To comment on this article, contact rdavidson@uspharmacist.com.
`
`We recommend
`
`Ondansetron 2 mg/mL Injection, Unpreserved
`Loyd V. Allen et al., US Pharmacist, 2012
`
`Diazepam 5 mg/mL Injection
`Loyd V. Allen et al., US Pharmacist, 2012
`
`Naproxen Sodium 100-mg/mL Injection
`Loyd V. Allen et al., US Pharmacist, 2009
`
`Fentanyl 50 mcg/mL Injection
`Loyd V. Allen et al., US Pharmacist, 2012
`
`Ribavirin 33 mg/mL Sterile Inhalation Solution
`Loyd V. Allen et al., US Pharmacist, 2014
`
`Owlstone Medical, Actelion Pharmaceuticals
`Partner to Develop Pulmonary Hypertension
`Breath Test
`Leo O'Connor et al., 360Dx, 2019
`
`Somalogic Exploring New Models for Selling
`Clinical Products Based on SomaScan
`System
`360Dx, 2018
`
`Glutamine metabolism in cancer therapy
`Tra-Ly Nguyen et al., Cancer Drug
`Resistance-OAE Publishing, 2018
`
`Wilms’ tumor gene ( WT1 ) is strongly
`expressed in high-risk subsets of pediatric
`acute lymphoblastic leukemia
`Fatih M. Uckun1 et al., Cancer Drug
`Resistance-OAE Publishing, 2018
`
`Body mass index and treatment response to
`subcutaneous abatacept in patients with
`psoriatic arthritis: a post hoc analysis of a
`phase III trial
`Iain B McInnes et al., Rheumatic &
`Musculoskeletal Diseases Open, 2019
`
`https://www.uspharmacist.com/article/l-cysteine-hydrochloride-50-mgml-injection
`
`5/7/2020
`
`Eton Ex. 1020
`4 of 5
`
`

`

`L-Cysteine Hydrochloride 50 mg/mL Injection
`
`Page 5 of 5
`
`Powered by
`
`Copyright © 2000 - 2020 Jobson Medical Information LLC unless otherwise noted. All
`rights reserved. Reproduction in whole or in part without permission is prohibited.
`
`https://www.uspharmacist.com/article/l-cysteine-hydrochloride-50-mgml-injection
`
`5/7/2020
`
`Eton Ex. 1020
`5 of 5
`
`

This document is available on Docket Alarm but you must sign up to view it.


Or .

Accessing this document will incur an additional charge of $.

After purchase, you can access this document again without charge.

Accept $ Charge
throbber

Still Working On It

This document is taking longer than usual to download. This can happen if we need to contact the court directly to obtain the document and their servers are running slowly.

Give it another minute or two to complete, and then try the refresh button.

throbber

A few More Minutes ... Still Working

It can take up to 5 minutes for us to download a document if the court servers are running slowly.

Thank you for your continued patience.

This document could not be displayed.

We could not find this document within its docket. Please go back to the docket page and check the link. If that does not work, go back to the docket and refresh it to pull the newest information.

Your account does not support viewing this document.

You need a Paid Account to view this document. Click here to change your account type.

Your account does not support viewing this document.

Set your membership status to view this document.

With a Docket Alarm membership, you'll get a whole lot more, including:

  • Up-to-date information for this case.
  • Email alerts whenever there is an update.
  • Full text search for other cases.
  • Get email alerts whenever a new case matches your search.

Become a Member

One Moment Please

The filing “” is large (MB) and is being downloaded.

Please refresh this page in a few minutes to see if the filing has been downloaded. The filing will also be emailed to you when the download completes.

Your document is on its way!

If you do not receive the document in five minutes, contact support at support@docketalarm.com.

Sealed Document

We are unable to display this document, it may be under a court ordered seal.

If you have proper credentials to access the file, you may proceed directly to the court's system using your government issued username and password.


Access Government Site

We are redirecting you
to a mobile optimized page.





Document Unreadable or Corrupt

Refresh this Document
Go to the Docket

We are unable to display this document.

Refresh this Document
Go to the Docket